Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 325-337

  Ulahannan, Susanna V ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiangiogenesis inhibitors; Bevacizumab; Non small cell lung cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DOCETAXEL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTEDANIB; INTERCELLULAR ADHESION MOLECULE 1; IRINOTECAN; IXABEPILONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTICOAGULATION; AREA UNDER THE CURVE; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRONCHOPLEURAL FISTULA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; EPISTAXIS; ESOPHAGITIS; EXFOLIATIVE DERMATITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POTASSIUM BLOOD LEVEL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX RATIO; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79953793443     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.554476     Document Type: Review

References (104)

1. American Cancer Society. Cancer Facts & Figures, 2009
2. American Cancer Society, Inc.: Atlanta, GA, 2009.
3. Jemal A, Siegel R,Ward E, Hao Y, Xu J,Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
4. Juergens R, Brahmer J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep 2007;9(4):255-264. (Pubitemid 47045160)
5. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009;6(2):233-241.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-98. (Pubitemid 34438899)
7. Blau HM, Banfi A.The well-tempered vessel. NatMed 2001;7(5): 532-534. (Pubitemid 32448310)
8. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273-286. (Pubitemid 46505878)
9. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-989. (Pubitemid 32937367)
10. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-974. (Pubitemid 43093963)
11. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6. (Pubitemid 20020880)
12. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-257.
13. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10. (Pubitemid 41680947)
14. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51(2):143-158. (Pubitemid 43144358)
15. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-676. (Pubitemid 36749215)
16. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706): 58-62. (Pubitemid 40093472)
17. Alvarez RH, Kantarjian HM, Cortes JE. Biology of plateletderived growth factor and its involvement in disease. Mayo Clin Proc 2006;81(9):1241-1257. (Pubitemid 44316290)
18. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16(2):159-178. (Pubitemid 40616114)
19. Jenab-Wolcott J,Giantonio BJ. Bevacizumab: current indications and future development formanagement of solid tumors. Expert Opin Biol Ther 2009;9(4):507-517.
20. FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer. Cancer BiolTher 2006;5(11):1425-1428.
21. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-2550. (Pubitemid 44917502)
22. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-2191. (Pubitemid 41095154)
23. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer. J Clin Oncol 2009;27(20):3284-3289.
24. Skaff ZG,Hageboutros A,Krieger K, Coakley S, Somer R, Stevenson J. A phase II trial of first-line bevacizumab in combinationwith pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S). Abstract e19091.
25. Dalsania CJ,Hageboutros A,Harris E, Krieger K,Vora C, Stevenson J. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous nonsmall cell lung cancer. J Clin Oncol 2007;25(18S). Abstract 18163.
26. Waples JM, Auerbach M, Steis R, Boccia RV, Wiggans RG. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04-015). J Clin Oncol 2008;26(15S). Abstract 19018.
27. Wozniak AJ, Kalemkerian GP, Gadgeel SM, Schneider BJ, Valdivieso M, Venkatramanamoorthy R, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JD. A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S). Abstract e19099.
28. Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008;3(5):511-515. (Pubitemid 351630279)
29. Leon L, Vazquez S, Gracia JM, Lazaro M, Firvida JL, Casal J, Amenedo M, Santome L, Gallego R, Anido U. Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): a Galician Lung Cancer Group phase II study. J Clin Oncol 2009;27(15S). Abstract e19089.
30. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2007;25(30):4743-4750. (Pubitemid 350086476)
31. Ferrer N, Cobo M, ParedesA,MendezM,Munoz-Langa J, Rueda A, Alverez de Mon M, Sanchez-Hernandez A, Gallego R, Torrego J. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic nonsquamous non-mall cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S). Abstract e19023.
32. Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L. Phase II trial of nanoparticle albuminbound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4(12):1537-1543.
33. Clement-DucheneC,Krupitskaya Y, Ganjoo K, Lavori P,McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol 2010;5(11):1821-1825.
34. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N,Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil. J Clin Oncol 2009;27(8):1227- 1234.
35. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM,Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11(8):733-740.
36. Fischbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T, for the ARIES Investigators. Preliminary safety and effectiveness of bevacizumab (BV)-based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol 2009;27(15S). Abstract 8040.
37. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28(4):614-619.
38. Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2008;3(10):1153- 1158.
39. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern CooperativeOncology Group Trial 4599. J Clin Oncol 2008;26(1):60-65.
40. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumaban Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14(5):1407-1412. (Pubitemid 351413922)
41. Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N,Mezger J, Archer V,Moore N,Manegold C. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21(9):1804-1809.
42. Mezger J, von Pawel J, Reck M. Bevacizumab (Bv) singleagent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results from an exploratory analysis of the AVAiL study. J Clin Oncol 2009;27(15S, May 20 supplement). Abstract e19001.
43. Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC. Treatment rationale and study design for the pointbreak study: a randomized, openlabel phase III study of pemetrexed/carboplatin/ bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/ carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous nonsmall-cell lung cancer. Clin Lung Cancer 2009;10(4):252-256.
44. William WN Jr, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced non-small cell lung cancer. Cancer 2010;116(10):2401-2408.
45. Hanna N, Shepherd FA, Fossella FV, Pereira JR, de MF, von PJ, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-1597. (Pubitemid 41079796)
46. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 2009;297(1): R1-R5.
47. van Heeckeren WJ, Ortiz J, CooneyMM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25(21):2993-2995. (Pubitemid 47218042)
48. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12(6):713-718. (Pubitemid 47036205)
49. Polikoff J, Hainsworth JD, Fehrenbacher L, Royer-Joo S, Mu Y, Strickland DK, Miller VA. Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with nonsmall cell lung cancer (NSCLC) treated on ATLAS. J Clin Oncol 2008;26(15S). Abstract 8079.
50. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W. Safety of bevacizumab in patients with non-small cell lung cancer and brain metastases. J Clin Oncol 2009;27;5255-5261.
51. Otterson GA, O'Connor PG, Lin M, Herbst RS, for the BETA Lung Investigators. Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. J Clin Oncol 2009;27(15S). Abstract e19025.
52. Hirsh V, Ramlau R, von Pawel J, Zatloukal P, Vera G, Leighl N, Mezger J, Archer V, Reck M. Final safety results of BO17704 (AVAiL): a phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S). Abstract 8039.
53. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28(6):949-954.
54. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-2143. Epub 2010 Apr 5. PMID: 20368558.
55. Hurwitz H, Douglas PS, Middleton JP, Sledge GW, JohnsonDH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010;28(7S). Abstract 3039.
56. Sandler AB, Schiller JH,Gray R,Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27(9):1405-1412.
57. Ivy SP, Wick JY, Kaufman BM. An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6(10):569-579.
58. Batchelor TT, Sorensen AG, di TE, Zhang WT, Duda DG, Cohen KS,Kozak KR,CahillDP, Chen PJ, ZhuM, AncukiewiczM, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95. (Pubitemid 46075199)
59. CasanovasO,HicklinDJ, BergersG,HanahanD.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309. (Pubitemid 41443415)
60. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-1295. (Pubitemid 36554699)
61. Erber R,Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-340.
62. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603.
63. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6(8):626-635. (Pubitemid 44140860)
64. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, LynchM, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099- 7109. (Pubitemid 39331023)
65. Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jr, Jett JR, Mandrekar SJ, Schild SE. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2007;25(18S). Abstract 7547.
66. Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10(Suppl 1), S7-S16.
67. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, BroseMS, Weber BL, Albertini MR, O'Dwyer PJ. A phase I trial of the oral,multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14(15):4836-4842.
68. Scagliotti G, Novello S, von PJ, Reck M, Pereira JR, ThomasM, brao Miziara JE, Balint B, de MF, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, DiMatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol 2010;28(11):1835-1842.
69. Gadgeel SM, Wozniak A, Edelman MJ, Valdivieso M, Heilbrun L, Venkatramanamoorthy R, Shields A, LoRusso P, Hackstock D, Ruckdeschel J. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent nonsmall cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S). Abstract e19007.
70. De Boer R, Humblet Y, Wolf J, Nogova L, Ruffert K, Milenkova T, Smith R, Godwood A, Vansteenkiste J. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer. Ann Oncol 2009;20(3):486-491.
71. Heymach JV, Paz-Ares L, De BF, Sebastian M, Stewart DJ, EberhardtWE, RanadeAA,CohenG, Trigo JM, SandlerAB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26(33):5407-5415.
72. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small cell lung cancer. J Clin Oncol 2007;25(27):4270-4277. (Pubitemid 47548567)
73. Herbst RS, Sun Y, EberhardtWE,Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11(7):619-626.
74. De Boer R, Arrieta O, Gottfried M, Blackhall FH, Raats J, Yang CH, Langmuir P, Milenkova T, Read J, Vansteenkiste J, Western Hospital, Melbourne, Australia, Instituto Nacional de Cancerolog a (INCan), Mexico City, Mexico, Meir Medical Center, Kfar Saba, Israel, Christie Hospital NHS Trust, Manchester, UK, Panorama Medical Center, Capetown, South Africa, National Taiwan University Hospital, Taipei, Taiwan, AstraZeneca,Wilmington, DE, AstraZeneca, Macclesfield, UK, University Hospital Leuven, Leuven, Belgium. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, doubleblind phase III trial (ZEAL). J Clin Oncol 2009;27(suppl):409s. Abstract 8010.
75. Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27(26):4274-4280.
76. Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol 2008;3(6, Suppl 2):S119-S123. (Pubitemid 351786741)
77. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, TyeL, Selaru P, Chao RC, Scagliotti GV. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J Clin Oncol 2008;26(4):650-656. (Pubitemid 351264362)
78. Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101(9):1543-1548.
79. Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I doseescalation study. Lung Cancer 2010;70(2):180-1877. Epub 2010 Feb 25.
80. Robert F, Sandler A, Schiller JH, Liu G, Harper K, Verkh L, Huang X, Ilagan J, Tye L, Chao R, Traynor AM. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010;66(4):669-680.
81. Nikolinakos P, Heymach JV.The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. JThorac Oncol 2008;3(6 Suppl 2):S131-S134. (Pubitemid 351786743)
82. Drevs J, Siegert P,MedingerM,Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25(21):3045-3054. (Pubitemid 47218051)
83. Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;64(6):1165-1172.
84. LoRusso PM, Heath E, Valdivieso M, Pilat M, Wozniak A, Gadgeel S, Shields A, Puchalski T, Ewesuedo R. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006;24(18S). Abstract 3034.
85. Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009;45(5):782-788.
86. Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008;26(11):1871-1878.
87. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, FentonD, Zukin M,WaldeD, Laberge F,VincentMD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advancednon-small cell lung cancer:NCICClinicalTrialsGroup BR24 study. J Clin Oncol 2010;28(1):49-55.
88. AstraZeneca. AstraZeneca provides update on cediranib (RECENTINTM, AZD2171) clinical development programme. HORIZON colorectal cancer programme continues into Phase III; BR24 non-small cell lung cancer trial will not progress. Retrieved on April 8, 2010, from . com/search/?itemId=2289031
89. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, FontaniniG, Bianco AR, Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9(4):1546-1556. (Pubitemid 36418413)
90. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, GrahamGA, Hughes GD,Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-4655.
91. Natale RB, Thongprasert S, Greco FA,Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Langmuir P, RowbottomJA, Goss GD. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009;27(15S):409s. Abstract 8009.
92. AstraZeneca. AstraZeneca Annual Report 2009. Therapy Area Review: Oncology: Cancer. Retrieved on April 14, 2010, from
93. Hilberg F, RothGJ, Krssak M,Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-4782.
94. von Pawel J, Kaiser R, Eschbach C, Love J, Staab A, Freiwald M, Bruno R, Stopfer P. Efficacy, safety and pharmacokinetic (PK) results of a phase II study with the triple angiokinase inhibitor BIBF 1120 in patients suffering from advanced non-small cell lung cancer (NSCLC). JThorac Oncol 2008;3(4 suppl 1):S61. Abstract 163O.
95. Camidge DR, Conkling P, Stephenson J, Glassman PM, Zhao Y, Kaiser R, Stopfer P. Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor, BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(15S). Abstract 3567.
96. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated nonsmall cell lung cancer patients. Clin Cancer Res 2010;16(10): 2881-2889.
97. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, CheungM. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7): 2012-2021. (Pubitemid 47052491)
98. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008;9(12):1324-1335.
99. Altorki N, LaneME, Bauer T, Lee PC, GuarinoMJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small cell lung cancer. J Clin Oncol 2010;28(19): 3131-3137.
100. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70(6):2171-2179.
101. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008;9(6):658-671. (Pubitemid 351777169)
102. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-5483.
103. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von PJ. Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: results from a phase II study. J Clin Oncol 2009;27(23): 3836-3841.
104. Martin LP, Kozloff MF, Krzakowski M, Samuel TA, Rado TA, Tarazi J, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Axtinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2009;27(15S). Abstract 3559.